非布司他国内上市没？

Has it been launched domestically? On June 22, the original Japanese drug Febuxostat (trade name: Fibre) for the treatment of gout was launched in China, and Astellas Pharmaceuticals (China) Co., Ltd. obtained the exclusive sales rights in the Chinese market.

Febuxostat is a drug used to treat gout caused by high uric acid levels. It is usually only recommended for patients who cannot take allopurinol. This product is not recommended for the treatment of asymptomatic hyperuricemia. Gout is a disease caused by disorders of purine metabolism. Generally speaking, in addition to the common hyperuricemia, there are also gouty acute arthritis, tophi deposition, tophi chronic arthritis, joint deformities, nephritis, and uric acid kidney stones. Hyperuricemia often refers to the situation where patients have fasting blood uric acid levels that are higher than normal under a normal purine diet. Patients may be asymptomatic, or may have conditions such as arthritis, gout, and high blood pressure.

With the changes in people's lifestyle and dietary structure, the prevalence of hyperuricemia in my country is increasing year by year and is trending younger. It has become the second largest metabolic disease after diabetes. The prevalence of gout caused by hyperuricemia is also showing a significant growth trend. According to epidemiological surveys, the current prevalence of gout in China is about 1.1%, and the number of affected people is about 16 million. It mostly affects men over 40 years old, and is mainly characterized by repeated attacks of severe joint pain. Patients with gout are often accompanied by comorbidities such as hypertension, chronic kidney disease, and diabetes, which increase the risk of all-cause mortality.

It is a xanthine oxidase (XO) inhibitor that combines with xanthine oxidase through a non-competitive mechanism to inhibit xanthine oxidase activity, thereby inhibiting the production of uric acid and achieving the purpose of reducing acidity. Therefore, it is suitable for the long-term treatment of hyperuricemia with gout symptoms. Febuxostat is a newly developed drug. At the same dose, febuxostat has a stronger effect in reducing blood uric acid. Therefore, when it comes to the choice of gout acid-lowering drugs, many patients prefer febuxostat.